![]() |
市場調查報告書
商品編碼
1541687
按應用分類的吸入一氧化氮市場報告(新生兒呼吸治療、慢性阻塞性肺病 (COPD)、急性呼吸窘迫症候群 (ARDS) 等)和地區 2024-2032Inhaled Nitric Oxide Market Report by Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS), and Others), and Region 2024-2032 |
IMARC Group年,全球吸入一氧化氮市場規模達9.437億美元。
吸入一氧化氮 (iNO) 是一種選擇性肺血管擴張劑,由三級新生兒加護病房 (NICU) 熟練醫生監督。它透過改善通氣-灌注不匹配和降低肺血管阻力升高和高血壓,有助於調節血管肌張力並治療新生兒低氧性呼吸衰竭。它還有助於改善氧合併減少對體外膜氧合(ECMO)的需求。目前,擴大使用 iNO 療法作為急性呼吸窘迫症候群 (ARDS) 患者的救援藥物。
新生兒呼吸系統疾病和其他後續疾病(例如持續性肺動脈高壓和新生兒缺氧性呼吸衰竭(HRF))的盛行率不斷增加,是顯著促進市場成長的主要因素之一。此外,相對更容易患高血壓、動脈粥狀硬化、周邊動脈疾病、心臟衰竭和血栓形成的老年人口不斷增加,也支持了市場的成長。此外,iNO 在治療慢性阻塞性肺病 (COPD)、氣喘和 ARDS 方面在全球範圍內獲得了巨大的關注。此外,高度傳染性的冠狀病毒病(COVID-19)的爆發以及全球範圍內感染人數的驚人增加正在對市場產生有利的影響。此外,iNO 療法也用於對抗冠狀病毒感染,因為它有助於改善重症肺炎患者的通氣/灌注。該市場也受到世界各地醫療保健行業正在進行的研究和開發(R&D)活動的推動,以改善整體患者體驗。
The global inhaled nitric oxide market size reached US$ 943.7 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,657.7 Million by 2032, exhibiting a growth rate (CAGR) of 6.3% during 2024-2032.
Inhaled nitric oxide (iNO) refers to a selective pulmonary vasodilator supervised by skilled physicians at tertiary neonatal intensive care units (NICUs). It assists in regulating vascular muscle tone and treating hypoxemic respiratory failure among newly born infants by improving ventilation-perfusion mismatch and reducing elevated pulmonary vascular resistance and hypertension. It also aids in improving oxygenation and decreasing the need for extracorporeal membrane oxygenation (ECMO). At present, there is a rise in the use of iNO therapy as a rescue agent for acute respiratory distress syndrome (ARDS) patients.
The increasing prevalence of respiratory and other subsequent diseases in newborns, such as persistent pulmonary hypertension and neonatal hypoxic respiratory failure (HRF), represents one of the primary factors significantly contributing to the market growth. Additionally, the rising geriatric population, which is relatively more prone to hypertension, atherosclerosis, peripheral artery disease, heart failure, and thrombosis, is supporting the growth of the market. Furthermore, iNO is gaining immense traction worldwide for treating chronic obstructive pulmonary diseases (COPD), asthma, and ARDS. Moreover, the outbreak of the highly contagious coronavirus disease (COVID-19) and an alarmingly increasing number of individuals getting infected on a global level are favorably influencing the market. Furthermore, iNO therapy is being used against coronavirus stains as it assists in improving ventilation/perfusion in patients with severe pneumonia. The market is also driven by the ongoing research and development (R&D) activities in the healthcare industry around the world to improve the overall patient experience.
IMARC Group provides an analysis of the key trends in each sub-segment of the global inhaled nitric oxide market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on application.
Neonatal Respiratory Treatment
Chronic Obstructive Pulmonary Disease (COPD)
Acute Respiratory Distress Syndrome (ARDS)
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Air Liquide S.A, Bellerophon Therapeutics, Beyond Air Inc., Linde plc, Mallinckrodt plc, Merck KGaA, Novoteris LLC, Nu-Med Plus and VERO Biotech LLC.